Discovery and combinatorial synthesis of fungal metabolites beauveriolides, novel antiatherosclerotic agents

Accounts of Chemical Research

Volumn 41, Issue 1, 2008, Pages 32-39

  Tomoda, Hiroshi ^a   Doi, Takayuki ^b  

^a KITASATO UNIVERSITY   (Japan)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEAUVEROLIDES; CHOLESTEROL ACYLTRANSFERASE; DEPSIPEPTIDE; ENZYME INHIBITOR; LIPID; UNCLASSIFIED DRUG;

ANIMAL; ARTERIOSCLEROSIS; ARTICLE; CHEMISTRY; COMBINATORIAL CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; DRUG SCREENING; MACROPHAGE; METABOLISM; METHODOLOGY; MOUSE; PHYSIOLOGY; STEREOISOMERISM; SYNTHESIS;

ANIMALS; ARTERIOSCLEROSIS; COMBINATORIAL CHEMISTRY TECHNIQUES; DEPSIPEPTIDES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; LIPIDS; MACROPHAGES; MICE; STEREOISOMERISM; STEROL O-ACYLTRANSFERASE;

EID: 38949148621     PISSN: 00014842     EISSN: None     Source Type: Journal    
DOI: 10.1021/ar700117b     Document Type: Article

References (51)

1. Endo, A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 1992, 33, 1569-1582.
2. Alberts, A. W.; Chen, J.; Kuron, G.; Hunt, V.; Huff, J.; Hoffman, C.; Rothrock, J.; Lopez, M.; Joshua, H.; Harris, E.; Patchett, A.; Monaghan, R.; Currie, S.; Stapley, E.; Albers-Schonberg, G.; Hensens, O.; Hirshfield, J.; Hoogsteen, K.; Liesch, J.; Springer, J. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 3957-3961.
3. Shepherd, J.; Cobbe, S. M.; Ford, I.; Isles, C. G.; Lorimer, A. R.; Macfarlane, P. W.; McKillop, J. H.; Packard, C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 1995, 333, 1301-1307.
4. Pedersen, T. R.; Kjekshus, A. G.; Berg, K.; Haghfelt, T.; Faergeman, O.; Thorgeirsson, G.; Pyorala, K.; Miettinen, T.; Olsson, A. G.; Wedel, H.; et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). Lancet 1995, 344, 1383-1389.
5. McKenney, J. M.; McCormick, L. S.; Schaefer, E. J.; Black, D. M.; Watkins, M. L. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am. J. Cardiol. 2001, 88, 270-274.
6. Shaw, M. K.; Newton, R. S.; Sliskovic, D. R.; Roth, B. D.; Ferguson, E.; Krause, B. R. Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase. Biochem. Biophys. Res. Commun. 1990, 170, 726-734.
7. Goldstein, J. L.; Ho, Y. K.; Basu, S. K.; Brown, M. S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 333-337.
8. Brown, M. S.; Goldstein, J. L.; Krieger, M.; Ho, Y. K.; Anderson, R. G. W. Reversible accumulation of cholesteryl esters in macrophages incubated with acetylated lipoproteins. J. Cell Biol. 1979, 82, 597-613.
9. Gerrity, R. G. The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am. J. Pathol. 1981, 103, 181-190.
10. Namatame, I.; Tomoda, H.; Arai, H.; Inoue, K.; Ōmura, S. Complete inhibition of mouse macrophage-derived foam cell formation by triacsin C. J. Biochem. 1999, 125, 319-327.
11. Namatame, I.; Tomoda, H.; Tabata, N.; Si, S.; Ōmura, S. Structure elucidation of fungal beauveriolide III, a novel inhibitor of lipid droplet formation in mouse macrophages. J. Antibiot. 1999, 52, 7-12.
12. Namatame, I.; Tomoda, H.; Si, S.; Yamaguchi, Y.; Masuma, R.; Ōmura, S. Beauveriolides, specific inhibitors of lipid droplet formation in mouse macrophages, produced by Beauveria sp. FO-6979. J. Antibiot. 1999, 52, 1-6.
13. Matsuda, D.; Namatame, I.; Tomoda, H.; Kobayashi, S.; Zocher, R.; Kleinkauf, H.; Ōmura, S. New beauveriolides produced by amino acid-supplemented fermentation of Beauveria sp. FO-6979. J. Antibiot. 2004, 57, 1-9.
14. Nishikawa, K.; Arai, H.; Inoue, K. Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages. J. Biol. Chem. 1990, 265, 5226-5231.
15. Mochizuki, K.; Ohmori, K.; Tamura, H.; Shizuri, Y.; Nishiyama, S.; Miyoshi, E.; Yamamura, S. The structures of bioactive cyclodepsipeptides, beauveriolides I and II, metabolites of entomopathogenic fungi Beauveria sp. Bull. Chem. Soc. Jpn. 1993, 66, 3041-3046.
16. Tomoda, H.; Namatame, I.; Si, S.; Kawaguchi, K.; Masuma, R.; Namikoshi, M.; Ōmura, S. Phenochalasins, inhibitors of lipid droplet formation in mouse macrophages, produced by Phomopsis sp. FT-0211. J. Antibiot. 1999, 52, 851-856.
17. Uchida, R.; Kim, Y.-P.; Namatame, I.; Tomoda, H.; Ōmura, S. Sespendole, a new inhibitor of lipid droplet synthesis in macrophages, produced by Pseudobotrytis terrestris FKA-250. J. Antibiot. 2006, 59, 93-97.
18. Koyama, N.; Nagahiro, T.; Yamaguchi, Y.; Ohshiro, T.; Masuma, R.; Tomoda, H.; Ōmura, S. Spylidone, a novel inhibitor of lipid droplet accumulation in mouse macrophages produced by Phoma sp. FKI-1840. J. Antibiot. 2005, 58, 338-345.
19. Koyama, N.; Ohshiro, T.; Tomoda, H.; Ōmura, S. Fungal isobisvertinol, a new inhibitor of lipid droplet accumulation in mouse macrophages. Org. Lett. 2007, 9, 425-428.
20. Namatame, I.; Tomoda, H.; Matsuda, D.; Tabata, N.; Kobayashi, S.; Ōmura, S. K97-0239A and B, inhibitors of macrophage foam cell formation, produced by Streptomyces sp. K97-0239. Proc. Jpn. Acad. 2002, 78, 45-50.
21. Namatame, I.; Matsuda, D.; Tomoda, H.; Yamaguchi, Y.; Masuma, R.; Kobayashi, S.; Ōmura, S. Selective production of fungal beauveriolide I or III by fermentation in amino acid-supplemented media. J. Antibiot. 2002, 55, 1048-1052.
22. Kleinkauf, H.; von Dohren, H. Application of peptide synthesis in the synthesis of peptide analogues. Acta Biochim. Pol. 1997, 44, 839-848.
23. Kleinkauf, H.; von Dohren, H. A nonribosomal system of peptide biosynthesis. Eur. J. Biochem. 1996, 263, 335-351.
24. Kleinkauf, H.; von Dohren, H. Enzymatic generation of complex peptides. Prog. Drug Res. 1997, 48, 27-53.
25. Kuzma, M.; Jegorov, A.; Kacer, P.; Havlicek, V. Sequencing of new beauveriolides by high-performance liquid chromatography and mass spectrometry. J. Mass Spectrom. 2001, 36, 1108-1115.
26. Elsworth, J. F.; Grove, J. F. Cyclodepsipeptides from Beauveria bassiana. Part 2. Beauverolides A to F and their relationship to isarolide. J. Chem. Soc. Perkin Trans. 1 1980, 4, 1795-1799.
27. Elsworth, J. F.; Grove, J. F. Cyclodepsipeptides from Beauveria bassiana. Bals. Part 1. Beauverolides H and I. J. Chem. Soc. Perkin Trans. 1 1977, 3, 270-273.
28. Grove, J. F. Cyclodepsipeptides from Beauveria bassiana. Part 3. The isolation of beauverolides Ba, Ca, Ja, and Ka. J. Chem. Soc. Perkin Trans. 1 1980, 3, 2878-2880.
29. Namatame, I.; Tomoda, H.; Ishibashi, S.; Ōmura, S. Antiatherogenic activity of fungal beauveriolides, inhibitors of lipid droplet accumulation in macrophages. Proc. Natl. Acad Sci. U.S.A. 2004, 101, 737-742.
30. Liscum, L.; Ruggiero, R. M.; Faust, J. R. The intracellular transport of low density lipoprotein-derived cholesterol is defective in Niemann-Pick type C fibroblasts. J. Cell Biol. 1989, 108, 1625-1636.
31. Aikawa, K.; Furuchi, T.; Fujimoto, Y.; Arai, H.; Inoue, K. Structure-specific inhibition of lysosomal cholesterol transport in macrophages by various steroids. Biochim. Biophys. Acta 1994, 1213, 127-134.
32. Debry, P.; Nash, E. A.; Neklason, D. W.; Metherall, J. E. Role of multidrug resistance P-glycoproteins in cholesterol esterification. J. Biol. Chem. 1997, 272, 1026-1031.
33. Sliscovic, D. R.; Trivedi, B. K. ACAT inhibitors: Potential anti-atherosclerotic agents. Curr Med. Chem. 1994, 1, 204-225.
34. Cases, S.; Novak, S.; Zheng, Y.-W.; Myers, H. M.; Lear, S. R.; Sande, E.; Welch, C. B.; Lusis, A. J.; Spencer, T. A.; Krause, B. R.; Erickson, S. K.; Farese, R. V. J. ACAT-2, a second mammalian acyl-CoA:cholesterol acyltransferase. J. Biol. Chem. 1998, 273, 26755-26764.
35. Oelkers, P.; Behari, A.; Cromley, D.; Billheimer, J. T.; Sturley, S. L. Characterization of two human genes encoding acyl coenzyme A: Cholesterol acyltransferase-related enzymes. J. Biol. Chem. 1998, 273, 26765-26771.
36. Farese, R. V., Jr. Acyl CoA:cholesterol acyltransferase genes and knockout mice. Curr. Opin. Lipidol. 1998, 9, 119-123.
37. Parini, P.; Davis, M.; Lada, A. T.; Erickson, S. K.; Wright, T. L.; Gustafsson, U.; Sahlin, S.; Einarsson, C.; Eriksson, M.; Angelin, B.; Tomoda, H.; Ōmura, S.; Willingham, M. C.; Rudel, L. L. ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver. Circulation 2004, 110, 2017-2023.
38. Ohshiro, T.; Rudel, L. L.; Ōmura, S.; Tomoda, H. Selectivity of microbial acyl-CoA: cholesterol acyltransferase inhibitors toword isozymes. J. Antibiot. 2007, 60, 43-51.
39. Tardif, J. C.; Gregoire, J.; L&'Allier, P. L.; Anderson, T. J.; Bertrand, O.; Reeves, F.; Title, L. M.; Alfonso, F.; Schampaert, E.; Hassan, A.; McLain, R.; Pressler, M. L.; Ibrahim, R.; Lesperance, J.; Blue, J.; Heinonen, T.; Rodes-Cabau, J. Avasimibe and progression of lesions on UltraSound (A-PLUS) investigators. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 2004, 110, 3372-3377.
40. Terasaka, N.; Miyazaki, A.; Kasanuki, N.; Ito, K.; Ubukata, N.; Koieyama, T.; Kitayama, K.; Tanimoto, T.; Maeda, N.; Inaba, T. ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice. Atherosclerosis 2007, 190, 239-247.
41. Fazio, S.; Linton, M. Failure of ACAT inhibition to retard atherosclerosis. N. Engl. J. Med. 2006, 354, 1307-1309.
42. Lada, A. T.; Davis, M.; Kent, C.; Chapman, J.; Tomoda, H.; Ōmura, S.; Rudel, L. L. Identification of ACAT1- and ACAT2-specific inhibitors using a novel, cell-based fluorescence assay: Individual ACAT uniqueness. J. Lipid Res. 2004, 45, 378-386.
43. Cho, K. H.; An, S.; Lee, W. S.; Paik, Y. K.; Kim, Y. K.; Jeong, T. S. Mass-production of human ACAT-1 and ACAT-2 to screen isoform-specific inhibitor: A different substrate specificity and inhibitory regulation. Biochem. Biophys. Res. Commun. 2003, 309, 864-872.
44. Nissen, S. E.; Tuzcu, E. M.; Brewer, H. B.; Sipahi, I.; Nicholls, S. J.; Ganz, P.; Schoenhagen, P.; Waters, D. D.; Pepine, C. J.; Crowe, T. D.; Davidson, M. H.; Deanfield, J. E.; Wisniewski, L. M.; Hanyok, J. J.; Kassalow, L. M. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N. Engl. J. Med. 2006, 354, 1253-1263.
45. Nagai, K.; Doi, T.; Sekiguchi, T.; Namatame, I.; Sunazuka, T.; Tomoda, H.; Ōmura, S.; Takahashi, T. Synthesis and biological evaluation of a beauveriolide analogue library. J. Comb. Chem. 2006, 8, 103-109.
46. Ohshiro, T.; Namatame, I.; Nagai, K.; Sekiguchi, T.; Doi, T.; Takahashi, T.; Akasaka, K.; Rudel, L. L.; Tomoda, H.; Omura, S. Absolute stereochemistry of fungal beauveriolide III and ACAT inhibitory activity of four stereoisomers. J. Org. Chem. 2006, 71, 7643-7649.
47. Evans, D. A.; Ennis, M. D.; Mathre, D. J. Asymmetric alkylation reactions of chiral imide enolates. A practical approach to the enantioselective synthesis of α-substituted carboxylic acid derivatives. J. Am. Chem. Soc. 1982, 104, 1737-1739.
48. Brooks, D. W.; Lu, L. D.-L.; Masamune, S. C-Acylierung unter praktisch neutralen Bedingungen. Angew. Chem. 1979, 91, 76-77.
49. Noyori, R.; Ohkuma, T.; Kitamura, M.; Takaya, H.; Sayo, N.; Kumobayashi, H.; Akutagawa, S. Asymmetric hydrogenation of β-keto carboxylic esters. A practical, purely chemical access to β-hydroxy esters in high enantiomeric purity. J. Am. Chem. Soc. 1987, 109, 5856-5858.
50. Nicolaou, K. C.; Xiao, X.-Y.; Parandoosh, Z.; Senyei, A.; Nova, M. P. Radiofrequency encoded combinatorial chemistry. Angew. Chem. Int. Ed. Engl. 1995, 34, 2289-2291.
51. Nicolaou, K. C.; Pfefferkorn, J. A.; Mitchell, H. J.; Roecker, A. J.; Barluenga, S.; Cao, G.-Q.; Affleck, R. L.; Lillig, J. E. Natural product-like combinatorial libraries based on privileged structures. 2. Construction of a 10 000-membered benzopyran library by directed split-and-pool chemistry using NanoKans and optical encoding. J. Am. Chem. Soc. 2000, 122, 9954-9967.